Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?

The gut microbiome and the intestinal immune system are driving contributors to inflammatory bowel diseases (IBD). Both have an important signalling factor in common: short-chain fatty acids (SCFAs). SCFAs (acetate, propionate and butyrate) are produced by bacterial fermentation in the gut and exert...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EBioMedicine Ročník 66; s. 103293
Hlavní autoři: Deleu, Sara, Machiels, Kathleen, Raes, Jeroen, Verbeke, Kristin, Vermeire, Séverine
Médium: Journal Article
Jazyk:angličtina
Vydáno: Netherlands Elsevier B.V 01.04.2021
Elsevier
Témata:
ISSN:2352-3964, 2352-3964
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The gut microbiome and the intestinal immune system are driving contributors to inflammatory bowel diseases (IBD). Both have an important signalling factor in common: short-chain fatty acids (SCFAs). SCFAs (acetate, propionate and butyrate) are produced by bacterial fermentation in the gut and exert several effects on host metabolism and immune system. This review provides an overview of the current knowledge of these effects, with specific focus on energy metabolism, intestinal barrier, immune system, and disease activity in IBD. To conclude, more research is needed on the cross-feeding mechanisms in the gut microbiome, as well as on the therapeutic potential of SCFAs on different disease models. Also randomized controlled trials and prospective cohort studies should investigate the clinical impact of SCFA administration.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:2352-3964
2352-3964
DOI:10.1016/j.ebiom.2021.103293